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Spontaneous VEGF Production by
Cultured Peritoneal Mesothelial Cells
from Patients on Peritoneal Dialysis
Long-term peritoneal dialysis (PD) may result in
increased peritoneal vascularization secondary to
neovascularization (1). Vascular endothelial growth
factor (VEGF) is the main factor known to participate
in new vessel formation (2). Peritoneal VEGF
production has to be an etiologic factor in peritoneal
neovascularization due to the relatively higher levels
found in peritoneal effluent than in plasma (3).
The exact origin of peritoneal effluent VEGF is not
known. Recently, pleural mesothelial cells (MC) have
been shown to produce small amounts of VEGF (4).
Also, VEGF has been detected in peritoneal capillary
endothelium and surrounding tissue in long-term PD
patients (5). Finally, the glucose degradation product
(GDP) carboxymethyl lysine has been demonstrated
to be co-localized with VEGF in the mesothelial layer
in chronic PD patients (6). These authors have also
shown the production of VEGF by rat MC exposed
to GDP.
Many usual conditions intrinsic to PD are related
to the VEGF present in the peritoneum in these patients.
Our hypothesis is that human MC might be a
source for VEGF. To study their potential VEGF production,
we determined VEGF levels in conditioned
medium during ex vivo culture of MC isolated from
the peritoneal effluent of active PD patients.
PATIENTS AND METHODS
Patients and Peritoneal Characteristics: We assessed
peritoneal antecedents and peritoneal function
by determining the mean number of prior
peritonitis episodes and the peritoneal transport parameters
[mass transfer coefficients (MTC) of urea
and creatinine and net ultrafiltration during a 4-hour
kinetic study with 2.27% glucose] (7) in 21 patients.
In addition, the accumulated peritoneal dose of glucose
administered during the complete PD period was
calculated for each patient.
Mesothelial cells (8) were isolated from nocturnal
peritoneal effluent incubated in hanging PD bags for
3 – 4 hours at 37°C. The residual effluent was removed
by vacuum suction with a sterile pipette, leaving approximately
200 mL in the bottom. Cells were resuspended
in this volume, transferred to four 50-mL
tubes, and washed twice with phosphate-buffered
saline by centrifugation at 1500 rpm for 20 minutes.
Then they were seeded in 25-cm2 tissue culture flasks
and incubated at 37°C in a humidified atmosphere
with 5% CO2, and maintained in M-199 (Biological
Industries, Kibbutz Beit Haemek, Israel) supplemented with 20% fetal bovine serum, 100
IU/mL penicillin,
100 :g/mL streptomycin, and 2% Biogro-2 (containing
insulin, transferrin, ethanol amine, and
putrescine) (Biological Industries). After reaching
confluence, cells were detached with trypsin/EDTA,
resuspended, and seeded in 24-well plates at 2 × 104
cells/well. Incubation was performed as before; the
medium was renewed every 3 – 4 days.
None of the cultures used to evaluate VEGF production
showed bacterial or fungal contamination.
Mesothelial cells were identified at isolation from effluent
and after trypsinization. Morphology was assessed
in cytospin optical microscopy slides (500 rpm)
stained with May–Grünwald–Giemsa. Mesothelial
cells were thus easily distinguished from macrophages,
lymphocytes, and neutrophils by their morphological
features defined under light microscope. No
atypical or giant cells were observed in these cultures.
Mesothelial cells were characterized by immunohistochemical
staining, identifying MC by their positive
staining for cytokeratin and negative staining for
CD45 (hematopoietic cells), HLA-DR (macrophages
and lymphocytes), and vWF (endothelial cells). All
antibodies were from Dako (Glostrup, Denmark).
VEGF165 Determinations: VEGF was measured in
the supernatant of 21 cultures of MC. VEGF determination
in supernatant was performed at day 13 of
seeding in 24-well plates, since the proliferation plateau
usually starts at this time while MC simultaneously
form a monolayer reaching confluence. This
time avoids vigorous cell proliferation, which is a consequence
of cell subconfluence state. After 48 hours
of serum deprivation, supernatant was taken for
analysis. VEGF165 was determined by enzyme immunoassay
(ELISA) with a kit from R&D Systems, Inc.
(Minneapolis, MN, U.S.A.).
Statistical Analysis: Data are expressed as mean ±
SD. The Mann–Whitney test was used for data comparisons
as a nonnormal distribution of the results
was found. Regression analysis was performed with
the Spearman test.
RESULTS
VEGF was detected in the supernatant from all
21 independent cultures of MC taken from PD bags
and grown in culture. All the values observed were
within the detection range for the ELISA kit, with
mean VEGF levels of 548 ± 518 pg/mL (range 59 –
1747 pg/mL). When peritoneal data and cell counts
from quartile 25 and quartile 75 were compared, no
significant differences were found (Table 1). Although
VEGF is also a vascular permeability factor, the levels
found in conditioned medium from MC in culture
are not related to peritoneal permeability to small
molecules.
Due to the wide range of values, the entire group
was artificially divided for supernatant VEGF levels
higher (n = 12) and lower (n = 9) than 200 pg/mL.
There was a trend toward a longer stay on PD in patients
with lower supernatant levels. The mesothelial
cell count on day 13 was similar for the two groups
(65 699 ± 28 738 vs 74 930 ± 39 245, p = 0.88); the
accumulated peritoneal glucose load was also similar
(72.06 ± 70.73 kg vs 122.41 ± 211.78 kg, p = 0.86).
We found no overall correlation between supernatant
VEGF levels and age, sex, time on PD, solute
transport characteristics (Table 2), ultrafiltration
rate, or accumulated dose of glucose. The MC count
at day 13 was not significantly correlated with VEGF
levels in the supernatant (r = –0.33, p = 0.13, NS).
Furthermore, correction of supernatant VEGF levels
according to the cell density at day 13 showed no
significant correlation with any of the independent
variables. We found no differences in supernatant
VEGF levels between the different types of MC
morphologies.
DISCUSSION
In the present study, we report the capacity of
peritoneal MC, cultured in vitro, to produce VEGF,
suggesting that MC may contribute to the neoangiogenesis
observed in some PD patients. This study
represents a direct demonstration of VEGF production
by human peritoneal MC in culture, and provides
an explanation for the significant amounts of
VEGF found in peritoneal effluent (3) and for its presence
at the mesothelial level (6). However, these findings
do not demonstrate the constitutive production
of VEGF by MC from nondialyzed peritoneum. VEGF
production by MC might be the result of an interaction
with the continuously administered dialysate.
In fact, pleural MC in culture from patients with cardiac
insufficiency produce VEGF in amounts below
the range of technique detection (4), much lower than
the levels we have found in peritoneal MC. The extreme
differences between the VEGF levels produced
by each cell population could be determined by the
particular situation of peritoneal MC in PD patients.
The amounts produced by peritoneal MC are closer
to the amounts produced by malignant pleural MC
than to those produced by nonmalignant cells (4).
No information has been found on VEGF production
by MC lines.
Although other peritoneal cells, such as macrophages,
are able to produce VEGF (9), there is no possibility
of interference by these cells in our study. By
our methodology (8), macrophages initially collected
from the peritoneal effluent are progressively eliminated
by washing, as they do not adhere to the flask
surface.800
We have demonstrated by analysis of supernatant
from cultured MC that peritoneal MC can produce
VEGF. This production is entirely spontaneous, although
we do not know whether it might be a response
to other stimuli. VEGF supernatant levels were independent
of the growth rate and number of MC. There
was a tendency toward an inverse relationship between
this number and the VEGF level, but it was
not statistically significant. The great variation in
levels found in our series is remarkable and is not
explained by any of the variables examined. The
analysis by extreme groups of values showed no significant
differences. The morphology of MC observed
after their growth in T-25 flasks did not differentiate
cells according to their VEGF-production capacity.
In consideration of the large amounts of glucose
present in the peritoneal cavity of PD patients, we
analyzed the impact of cumulative glucose overload
on VEGF levels during the whole PD period. However,
glucose overload was not correlated with supernatant
VEGF levels. It is necessary to involve other
complementary factors in this potentially pathogenic
pathway. High glucose levels are the main factor implicated
in ocular angiogenesis in diabetic patients,
mediated by VEGF overexpression by retinal epithelial
cells (10).
In conclusion, our study demonstrates the ex vivo
VEGF production by peritoneal mesothelial cells from
PD patients. The great difference with respect to pleural
mesothelial cells in the capacity of VEGF synthesis
suggests that, possibly, factors related to PD
influence this production. It is necessary to carry the
research further and explain why mesothelial cells
produce different amounts of VEGF.
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TABLE 2
Individual Values of Supernatant VEGF and
Peritoneal Mass Transfer Coefficients (MTC)
of Urea and Creatinine
Urea MTC Creatinine MTC VEGF level VEGF corrected
(mL/min) (mL/min) (pg/mL) by # cells
25.7 11.0 1448 70.2
17.5 9.9 175 9.7
19.3 13.0 662 9.3
23.5 9.2 558 7.4
27.2 10.8 780 11.6
43.3 26.2 125 1.7
21.6 8.5 184 2.9
22.9 14.2 483 5.1
35.7 14.2 1369 11.7
20.6 6.0 837 13.0
18.0 9.5 193 3.5
25.9 16.4 285 3.1
14.8 8.6 639 8.5
24.0 12.7 59 1.2
12.8 7.0 59 0.4
16.5 10.2 1747 69.9
17.5 6.9 172 1.9
10.6 2.1 127 1.3
24.0 9.2 1340 29.4
20.0 10.6 93 1.4
17.4 6.2 686 16.9
VEGR = vascular endothelial growth factor.
Normal ranges: urea MTC 18 – 22 mL/minute; creatinine
MTC 7 – 11 mL/minute.
TABLE 1
Characteristics of Patients with Extreme VEGF Supernatant Levels
VEGF quartile 25 VEGF quartile 75 p Value
Supernatant VEGF (pg/mL) 92.7±33.7 1348±328 <0.01
Mesothelial cells (N) 89 250±42 663 54 513±39 006 0.21
Age (years) 61.1±8.6 55±21 0.57
Months on PD 54.1±88 21.5±19 0.4
Episodes of peritonitis 1.4±2.6 0.8±1.3 0.6
Accumulated glucose load (kg) 156.1±287 84.3±66 0.6
Creatinine MTC (mL/min) 11.7±9 10.1±3 0.7
Urea MTC (mL/min) 22.1±13 24.4±7.1 0.7
Ultrafiltration (mL/4 hr, 2.27% glucose) 650±339 540±124 0.5
VEGR = vascular endothelial growth factor; PD = peritoneal dialysis; MTC = mass transfer
coefficient.
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